High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis

J Rheumatol. 2011 Jun;38(6):979-82. doi: 10.3899/jrheum.101261. Epub 2011 Mar 1.

Abstract

Objective: To investigate whether levels of anti-cyclic citrullinated peptide antibodies (anti-CCP2) in patients with rheumatoid arthritis (RA) are associated with the co-occurrence of lung diseases.

Methods: A total of 252 RA patients were included in a cross-sectional study. Pulmonary disease was confirmed by high-resolution chest computed tomography scan. Circulating anti-CCP2 were quantified using ELISA. Multivariate logistic regression was conducted to identify independent risk factors for lung disease.

Results: Male sex (OR 3.29, 95% CI 1.59-6.80) and high anti-CCP2 levels (OR 1.49, 95% CI 1.25-1.78) were identified as independent risk factors for lung disease in the RA population.

Conclusion: High anti-CCP2 levels are associated with lung disease in the RA population.

MeSH terms

  • Arthritis, Rheumatoid / epidemiology*
  • Arthritis, Rheumatoid / immunology*
  • Autoantibodies / blood*
  • Biomarkers / blood
  • Case-Control Studies
  • Comorbidity
  • Cross-Sectional Studies
  • Female
  • Humans
  • Logistic Models
  • Lung Diseases / diagnostic imaging
  • Lung Diseases / epidemiology*
  • Lung Diseases / immunology*
  • Male
  • Peptides, Cyclic / immunology*
  • Predictive Value of Tests
  • Risk Factors
  • Sex Factors
  • Tomography, X-Ray Computed

Substances

  • Autoantibodies
  • Biomarkers
  • Peptides, Cyclic
  • cyclic citrullinated peptide